Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Journal of the American Heart Association - Tập 7 Số 24 - 2018
Konstantinos Katsanos1, Stavros Spiliοpoulos2, Panagiotis Kitrou3, Μiltiadis Krokidis4, Dimitrios Karnabatidis5
1Konstantinos Katsanos Patras University Hospital, Rion, Greece
2Stavros Spiliopoulos Attikon University Hospital, Athens, Greece
3Panagiotis Kitrou Patras University Hospital, Rion, Greece
4Miltiadis Krokidis Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
5Dimitrios Karnabatidis Patras University Hospital, Rion, Greece

Tóm tắt

Background Several randomized controlled trials ( RCT s) have already shown that paclitaxel‐coated balloons and stents significantly reduce the rates of vessel restenosis and target lesion revascularization after lower extremity interventions.

Methods and Results A systematic review and meta‐analysis of RCT s investigating paclitaxel‐coated devices in the femoral and/or popliteal arteries was performed. The primary safety measure was all‐cause patient death. Risk ratios and risk differences were pooled with a random effects model. In all, 28 RCT s with 4663 patients (89% intermittent claudication) were analyzed. All‐cause patient death at 1 year (28 RCT s with 4432 cases) was similar between paclitaxel‐coated devices and control arms (2.3% versus 2.3% crude risk of death; risk ratio, 1.08; 95% CI, 0.72–1.61). All‐cause death at 2 years (12 RCT s with 2316 cases) was significantly increased in the case of paclitaxel versus control (7.2% versus 3.8% crude risk of death; risk ratio, 1.68; 95% CI, 1.15–2.47; —number‐needed‐to‐harm, 29 patients [95% CI , 19–59]). All‐cause death up to 5 years (3 RCT s with 863 cases) increased further in the case of paclitaxel (14.7% versus 8.1% crude risk of death; risk ratio, 1.93; 95% CI , 1.27–2.93; —number‐needed‐to‐harm, 14 patients [95% CI , 9–32]). Meta‐regression showed a significant relationship between exposure to paclitaxel (dose‐time product) and absolute risk of death (0.4±0.1% excess risk of death per paclitaxel mg‐year; P <0.001). Trial sequential analysis excluded false‐positive findings with 99% certainty (2‐sided α, 1.0%).

Conclusions There is increased risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the lower limbs. Further investigations are urgently warranted.

Clinical Trial Registration URL : www.crd.york.ac.uk/PROSPERO . Unique identifier: CRD 42018099447.

Từ khóa


Tài liệu tham khảo

10.1161/CIR.0000000000000470

10.1016/j.jacc.2010.08.606

10.1007/s00270-014-0876-3

10.1016/j.jvs.2014.01.041

10.1111/eci.12407

10.1016/j.ijcard.2013.06.081

Kayssi A, Al‐Atassi T, Oreopoulos G, Roche‐Nagle G, Tan KT, Rajan DK. Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016:CD011319.

10.1016/j.jacc.2014.06.1198

10.1161/CIRCULATIONAHA.115.016900

10.1161/CIRCINTERVENTIONS.117.005891

10.1161/CIRCULATIONAHA.114.011004

10.1161/CIRCULATIONAHA.106.687186

10.1136/bmj.d5928

10.1136/bmj.b2535

10.1161/CIRCINTERVENTIONS.112.969972

Begg CB. Publication bias. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY, US: Russell Sage Foundation; 1994:399–409.

10.1186/s12874-017-0315-7

10.1016/j.avsg.2018.04.014

10.1016/j.jacc.2013.03.034

Goueffic Y. BATTLE trial: 1 year outcomes in a multicenter randomized trial comparing MISAGO® vs. ZILVER® PTX® for the treatment of intermediate length femoropopliteal lesions. Charing Cross Symposium. April 2018; Oral presentation.

10.1186/1745-6215-15-423

10.1161/CIRCINTERVENTIONS.118.006564

10.1161/CIRCINTERVENTIONS.111.962324

FDA . Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130024S009B.pdf. Accessed August 30 2018.

FDA . Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140010S015B.pdf. Accessed August 25 2018.

10.1056/NEJMoa1406235

10.1016/j.jcin.2013.05.022

10.1056/NEJMoa0706356

10.1161/CIRCULATIONAHA.107.735985

10.1007/s00270-018-1940-1

Banyai M. Lutonix SFA long lesion study two year results. LINC symposium. January 2018; Oral presentation.

Brodmann M. ILLUMENATE European randomized trial: 2‐year results. LINC symposium. January 2018; Oral presentation.

Fanelli F. Optimal DCB performance LEVANT 2 and global SFA real‐world registry. LINC symposium. January 2017; Oral presentation.

10.1177/1526602817745565

10.1161/CIRCULATIONAHA.116.026493

10.1007/s00270-017-1713-2

10.1177/1526602817710770

10.1583/JEVT-12-3926MR.1

Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The “DEBELLUM”—lower limb multilevel treatment with drug eluting balloon—randomized trial: 1‐year results. J Cardiovasc Surg (Torino). 2014;55:207–216.

Guo W. 2‐year results of the ACOART‐I. LINC symposium. January 2018; Oral presentation.

Iida O. 2 year results from the MDT‐2113 SFA Japan trial—DCB vs.standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA. LINC symposium. January 2018; Oral presentation.

10.1016/j.jcin.2016.06.055

10.1161/CIRCULATIONAHA.117.028893

10.1177/1526602814564383

10.1161/CIRCINTERVENTIONS.112.971630

10.1016/j.avsg.2018.04.042

Teichgraber U Lehmann T Aschenbach R Scheinert D Zeller T Brechtel K Blessing E Lichtenberg M Thieme M. EffPac‐Trial: effectiveness of LUMINOR® DCB versus POBA in the SFA: 12 months results. Charing Cross Symposium. April 2018; Oral presentation.

PMDA . Available at: http://www.pmda.go.jp/medical_devices/2017/M20170830001/780045000_22900BZX00252000_A100_1.pdf. Accessed May 30 2018.

10.1177/1526602817725062

10.1016/j.jcin.2013.07.010

10.1161/CIRCULATIONAHA.116.025329

Tacke J. The randomized Freeway Stent Study completed the 12‐month follow‐up and favored the use of drug‐eluting balloons over plain balloons for the postdilatation of nitinol stents in the SFA and PI segments to lower restenosis rate. CIRSE symposium. September 2017; Oral presentation.

10.1016/j.jcin.2016.04.012

10.1161/CIRCULATIONAHA.115.017364

10.1161/JAHA.117.006321

Laird J. Long term durability of DCB treatment in the SFA: 4‐year results of the IN.PACT SFA study. LINC symposium. January 2018; Oral presentation.

10.1016/j.jcin.2014.07.023

10.1111/j.1467-985X.2008.00552.x

10.1136/eb-2018-102911

10.1186/1471-2288-9-86

10.1177/003591576505800503

10.1016/j.jcin.2015.03.020

10.1136/openhrt-2014-000117

10.1161/circinterventions.111.967794

10.1016/j.jcin.2011.03.005

10.1016/j.jacc.2015.10.043

10.1161/01.cir.0000138929.71660.e0

10.1002/ccd.22468

10.1161/01.CIR.96.2.636

10.1016/j.jvir.2010.12.027

10.1016/j.addr.2017.05.015

Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos. 1995;23:506–512.

10.1002/ccd.24995

10.1007/s10557-016-6658-1

10.1017/CBO9780511803161

10.1093/ije/dyw328

10.1016/j.jcin.2017.04.041

10.1016/j.jcin.2018.02.019

10.1038/srep45833

Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;4:CD005263.

10.1001/jama.2015.14851

10.1016/j.jacc.2015.09.063

Thông tin
Thông tin xuất bản

Journal of the American Heart Association

Tập 7 Số 24

Thông tin tác giả